ANS Biotech

Cellvax, founded in 2001, is a preclinical CRO which provides innovating drug validation studies both in vitro and in vivo allowing to accelerate the drug development process for unmet needs related to severe human diseases, mainly in Cancer and Osteoarthritis (OA) fields. Cellvax is a fast-growing technology-driven preclinical service company. Today, Cellvax directly employs and through R&D collaborations motivated and differently skilled scientists and engineers, working in interdisciplinary teams on several innovative products.

What we do:
Offspring Biosciences provides contract research services to the Pharma and Biotech industry, using advanced histopathology-based analytical techniques.

Who we are
The company is managed by Anders Ericsson-Dahlstrand, Dan Sunnemark and Anne Svensson, former senior scientists at AstraZeneca's now closed R&D unit in Södertälje, Sweden. We bring extensive and solid experience supporting drug discovery teams targeting neurodegenerative diseases (Alzheimers, Parkinsons and Huntingtons disease), diabetes and oncology, with highly informative and reliable data for critical Stop/Go decisions.

Our services
- Full study deliveries (design, execution, analyses and reporting)
- Target validation studies in tissues from pre-clinical disease models
and in human tissue
- Profiling of drug binding properties, including demonstrating target engagement and performing tissue cross reactivity analyses
- Evaluating effects in pre-clinical drug treatment studies
- Evaluating side effect risks
- Supporting translational research activites
- Animal and human tissue sourcing, validation and characterization
- Crititical review of literature data regarding quality, gap and risk
- Extended services via strategic collaborations (eg tissue banking, in vivo pharmacology, bioanalysis, radiochemistry, whole body autoradiography, human and veterinary pathology)

- Right Target
- Right Drug
- Right Efficacy
- Right Safety

For further information, please visit our website
www.offspringbiosciences.se

or contact us at:

contact@offspringbiosciences.se

When identifying problems is not enough....

XenoGesis is a laboratory-based contract research organisation (CRO) specialised in preclinical drug metabolism & pharmacokinetics (DMPK), quantitative bioanalysis and expert interpretation. The core XenoGesis team has an enviable track record of delivery in drug discovery.


It is clear that identifying poor compounds early through scientific rigor is key in preventing progression into more expensive pre-clinical tests. Even a minor improvement in early-stage drug failure prediction will result in significant time and cost savings for R&D companies. Specifically, XenoGesis can identify the potential ‘winners’ and ‘losers’ in a selection of compounds synthesised in drug discovery campaigns. Moreover, providing iterative feedback to the research team based on the results and recommending next steps is a key focus for XenoGesis.

We combine our state-of-the-art in vitro, in vivo and bioanalytical capabilities with our expert pharmacokinetic/pharmacodynamic (PK/PD) data interpretation services.

Using this integrated approach we provide you with the information required to successfully achieve your drug discovery goals.

XenoGesis was acquired by Sygnature Discovery in September 2020.

AGINKO Research is the premiere CRO for preclinical work in osteoarticular pathologies. We offer a wide range of contract research services to support Drug and Medical Device established companies as well as start-ups and academia. From industry standard protocols to customized research design, our animal models and assays, both on an in vivo or in vitro basis, provide key tools for compound discovery and product development.

Given our expertise, know-how, and network in the field of osteoarticular pathologies, AGINKO today also offers a full range of histology services for your preclinical and clinical trials as well as general consulting services (e.g., regulatory, strategy, financing) devoted to osteoarticular pathologies.


#Osteoarticular #CRO #Cartilage #Repair #Arthritis #Fracture #Osteoporosis #Preclinical #Pain #Disc #Spine #Infection

BioCentrum's mission is to create a platform for our clients and partners in order to help them translate innovative discoveries into preclinical candidates with improved chances to become marketed in the least amount of time possible. Our offer is a range of in vitro and in vivo assays that are created toward incorporating preclinical information into your pipeline.